OncoCyte has launched the DetermaRx, test for identifying early-stage lung cancer patients who may benefit from adjuvant chemotherapy after surgical resection. The test was formerly known as the Razor treatment stratification test and was being developed by Razor Genomics, which OncoCyte acquired in September. Regulators in Canada have approved the test for marketing in that country, the Irvine, California-based firm said. In the US, Florida Precision Oncology and the Leonard Cancer Institute at Mission Hospital in Mission Viejo, California have signed up as early access users of the test, OncoCyte said. It said that in a clinical study, high-risk patients identified by the test post-surgery and treated with adjuvant chemotherapy had a "significant" increase in survival rates.